key: cord-0985744-uq3jcdsw
authors: Charwudzi, Alice; Meng, Ye; Hu, Linhui; Ding, Chen; Pu, Lianfang; Li, Qian; Xu, Mengling; Zhai, Zhimin; Xiong, Shudao
title: Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma
date: 2021-11-02
journal: PeerJ
DOI: 10.7717/peerj.12394
sha: cf416e9a6613546bbf4bd4b51d1840f01ad493aa
doc_id: 985744
cord_uid: uq3jcdsw

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy with varied outcomes. However, the fundamental mechanisms remain to be fully defined. AIM: We aimed to identify core differentially co-expressed hub genes and perturbed pathways relevant to the pathogenesis and prognosis of DLBCL. METHODS: We retrieved the raw gene expression profile and clinical information of GSE12453 from the Gene Expression Omnibus (GEO) database. We used integrated bioinformatics analysis to identify differentially co-expressed genes. The CIBERSORT analysis was also applied to predict tumor-infiltrating immune cells (TIICs) in the GSE12453 dataset. We performed survival and ssGSEA (single-sample Gene Set Enrichment Analysis) (for TIICs) analyses and validated the hub genes using GEPIA2 and an independent GSE31312 dataset. RESULTS: We identified 46 differentially co-expressed hub genes in the GSE12453 dataset. Gene expression levels and survival analysis found 15 differentially co-expressed core hub genes. The core genes prognostic values and expression levels were further validated in the GEPIA2 database and GSE31312 dataset to be reliable (p < 0.01). The core genes’ main KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichments were Ribosome and Coronavirus disease-COVID-19. High expressions of the 15 core hub genes had prognostic value in DLBCL. The core genes showed significant predictive accuracy in distinguishing DLBCL cases from non-tumor controls, with the area under the curve (AUC) ranging from 0.992 to 1.00. Finally, CIBERSORT analysis on GSE12453 revealed immune cells, including activated memory CD4(+) T cells and M0, M1, and M2-macrophages as the infiltrates in the DLBCL microenvironment. CONCLUSION: Our study found differentially co-expressed core hub genes and relevant pathways involved in ribosome and COVID-19 disease that may be potential targets for prognosis and novel therapeutic intervention in DLBCL.

Diffuse large B-cell lymphoma (DLBCL) is exceptionally heterogeneous and the most common aggressive non-Hodgkin lymphoma (NHL) subtype in adults. It is increasingly appreciated that its varied outcomes depend on the patients' clinical and biological features (Karube et al., 2018; Liu et al., 2019b; Luo et al., 2018; Naresh et al., 2011) . Despite several reports on the mechanism of DLBCL, its pathogenesis characterized by multiple abnormalities at different molecular levels remains unresolved. Its development and progression are multifaceted, comprising various signaling pathways and driver genes. Despite improved clinical outcomes with current therapies, such as rituximabchemotherapy (R-CHOP), chimeric antigen receptor (CAR)-T cell, and advancement in stem cell transplantation, over 40% of high-risk patients relapse or develop the primary refractory disease. Mortality figures remain high (Karube et al., 2018; Luo et al., 2018) . Therefore, an in-depth understanding of disease biology could reveal novel biomarkers of diagnostic and prognostic value. It will also facilitate the design of alternative personalized therapeutic strategies for DLBCL.

Advances in gene profiling technologies, high-throughput data, and bioinformatics databases make screening DLBCL for differentially co-expressed genes indispensable, particularly when integrated with personalized genomic profile data (Lui et al., 2015; van Dam et al., 2018) . Recently, Liu et al. (2019a) identified eleven genes associated with endometrial cancer progression and prognosis by comprehensive bioinformatics analysis. Zhou et al. (2019) used CIBERSORT and other bioinformatics analyses for colon cancer. They found that the tumor microenvironment (TME) was abundantly enriched with M0 and M2 macrophages, activated memory CD4 + T cells, and other immune cells that could play crucial roles as biomarkers (Zhou et al., 2019) . However, few integrated bioinformatics studies have compared the gene expression profile of DLBCL with non-cancer controls.

Thus, we downloaded the Gene Expression Omnibus (GEO) raw dataset of GSE12453 and compared 11 DLBCL cases with 24 non-cancer controls (non-neoplastic B lymphocytes isolated from blood or tonsils). We performed a series of screens and analyses, including filtering off differentially expressed genes (DEGs), enrichment analysis, and co-expression analysis to determine hub genes of clinical significance to DLBCL. We identified 15 differentially co-expressed core hub genes associated with the prognosis of DLBCL (RPS24, RPS21, RPL31, RPL30, RPS17, MRPS28, FAU, RPS25, RPL22L1, NDUFA6, CXCL9, CCL4, MRPL33, HEBP1, and RPL11). The KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis associated most of the genes with Ribosome and Coronavirus disease-COVID-19 pathways. Validation in the GEPIA2 database and GSE31312 dataset revealed that the core genes had consistent expression levels and were reliable. Receiver operating characteristic (ROC) curves plotted demonstrated that the core genes could be potential diagnostic biomarkers. The identified genes could play critical roles in diagnosis, prognosis, and help establish a foundation for developing or identifying novel targeted therapies for DLBCL.

We evaluated and downloaded the raw gene expression profiles from the National Center for Biotechnology Information-Gene Expression Omnibus (NCBI-GEO) database (https:// www.ncbi.nlm.nih.gov/geo/). The series was based on GPL570 Affymetrix Human Genome U133 Plus 2.0 Array. GSE12453 (Brune et al., 2008) was used to identify differentially expressed and co-expressed genes. It was also used to predict tumor-infiltrating immune cells (TIICs). It contained 11 DLBCL cases and 25 normal controls. The controls were non-neoplastic B lymphocytes isolated from healthy donors' blood or tonsils from routine tonsillectomy patients. Similar expression profiles on the selected GPL570 platform contained normal but reactive controls or non-human controls, such as cell lines or limited controls, and were excluded. We used the GSE31312 (Visco et al., 2012) with 498 DLBCL cases for survival analysis and identifying immune cells infiltrating the TME.

The GSE12453 CEL file was pre-processed using the Affymetrix package (Gautier et al., 2004) in R software (https://www.r-project.org/) version 4.0.2 (Team, 2019) . The procedures included background correction, log 2 transformation, followed by quantile normalization. We performed a standard quality assessment, including scaling factors and NUSE plots, and hierarchical clustering to identify outliers. The study's design flowchart is shown in Fig S1. 

The DEGs between DLBCL cases and non-cancer controls were screened with R package limma (https://www.bioconductor.org/), Release 3.11 (Ritchie et al., 2015) . The cutoff criteria were p < 0.05, |log 2 fold change (FC)| > 1.0. The pheatmap package was used to generate hierarchical clustering, and ggplot2 (Wickham, 2016) was used to show the volcano plot in R. We used the resulting data output tables that included gene ID, log 2 FC, unadjusted and adjusted p-values in subsequent analyses.

We investigated the functional roles and pathway signaling relevance of the DEGs. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed using the R clusterprofiler (https:// bioconductor.org/), Release 3.12 (Yu et al., 2012) . A p-value < 0.05 was considered significantly enriched. The GO categories included biological process (BP), molecular function (MF), and cellular component (CC).

We used the normalized expression dataset of GSE12453 for the GSEA (www.gsea-msigdb. org/gsea/index.jsp), version 4.1.0. We followed the recommended protocol. This included "gct" and "cls" file formats for the expression dataset and phenotype labels, respectively Identifying differentially co-expressed hub module genes

The hub genes were identified from the intersection between the DEGs and genes significant in the WGCNA modules. We then analyzed the hub genes with the STRING and Cytoscape databases. We further conducted functional and pathway analysis on the hub genes to determine the relevant genes that impact DLBCL.

We validated the expression levels of the hub genes in the GEPIA2 (gepia2.cancer-pku.cn/ #index) database (Tang et al., 2019) . We retrieved the pre-processed quantile normalized series matrix file (GSE31312, Affymetrix HG-U133 Plus 2.0 GeneChips) containing 498 de-novo adults DLBCL from the NCBI-GEO database. We used it for the prognostic value analysis (overall survival (OS) and progression-free survival (PFS)). We plotted Kaplan-Meier survival curves with ggplot2 in R. The genes with p-value < 0.05 were selected as core hub genes. Also, receiver operating characteristic (ROC) curves were plotted with the pROC R package (Team, 2019) to validate the diagnostic value of the core genes. Then, the human protein atlas (proteinatlas.org/) was used to confirm their protein expressions in some selected lymph node samples (Uhlen et al., 2017) .

We used the ssGSEA (single-sample Gene Set Enrichment Analysis) package (Subramanian et al., 2005) in R on the GSE31312 dataset to investigate immune-associated core hub genes in the TME.

In addition, we also employed the GEPIA2 and Oncomine (Rhodes et al., 2004) databases to determine the expression levels and relevance of the core hub genes in other tumors.

According to standard protocols, one poor quality control sample (GSM312887) was excluded from the GSE12453 dataset after pre-processing. We identified 1,260 DEGs between the 11 DLBCL and 24 non-tumor controls. They comprised 1,014 up-regulated and 246 down-regulated genes (p < 0.05 and |log 2 FC| > 1). The gene list, Affymetrix probe ID, and log FC are shown in (Excel S1). The expression patterns of the DEGs are shown in Fig. 1 . Figure 1A shows the volcano plot of all expressed genes. The DLBCL cases showed a distinctive gene expression profiling. As shown in Fig. 1B , the heatmap of the top 169 DEGs with |log 2 FC| > 2 suggested that the identified DEGs expression levels could differentiate DLBCL from non-tumor samples. We utilized the CytoHubba application in Cytoscape, employing five calculation methods: the Maximal Clique Centrality (MCC), Maximum Neighborhood Component (MNC), Degree, Edge Percolation Component (EPC), and EcCentricity to rank the top 250 DEGs. The genes from the five methods were intersected using the Venn diagram software (http://bioinformatics.psb.ugent.be/webtools/Venn/). Most of the intersecting genes ( Fig. 1C) were associated with significant and valuable pathways such as the proteasome, spliceosome, and viral protein interaction with cytokine and cytokine receptor (Fig. S2 ). Intersecting genes are common genes with a high degree of interconnection and are more likely to represent key candidate genes with important biological regulatory functions.

We applied the enrichGO or enrichKEGG function of the clusterProfiler package (Yu et al., 2012) in R to investigate the biological functions of all the DEGs (p < 0.05). The GO and KEGG pathway analysis results are shown in Fig. 2 . In GO analysis, the DEGs were primarily enriched in ATP synthesis coupled electron transport and mitochondria ATP synthesis coupled electron transport for biological processes (BP). Their cellular components (CC) were mainly related to the mitochondria protein complex, mitochondria inner membrane, etc. Their molecular functions (MF) consisted of structural constituents of ribosomes and NADH dehydrogenase activity ( Fig. 2A) . The KEGG pathway analysis showed significant enrichment in ribosome and oxidative phosphorylation ( Fig. 2B) . Strikingly, the DEGs involved in the KEGG pathway and GO enrichment analysis were mainly upregulated genes, with few down-regulated genes.

Further analysis showed that the down-regulated genes were enriched in B cell activation (adjust p-value = 0.003) for GO-BP; our data showed no other significant GO and KEGG enrichment for the down-regulated genes. The GO and KEGG enrichment analysis for the upregulated genes was similar to the analysis we performed earlier. The GO and KEGG analysis classifies genes into functional categories to help understand their functions and regulatory pathways. Hence, with additional investigations, the genes in these pathways might throw more light on the pathogenesis of DLBCL.

We performed a GSEA analysis to compare the DLBCL and non-tumor controls' expression profiles to understand better the biological functions of the relevant genes discovered. We analyzed all the qualified genes in the GSE12453 expression dataset. The KEGG output from the GSEA was similar to our previous pathway analysis and confirmed our earlier results. The Hallmark gene sets showed immune and metabolicrelated signaling predominance, including estrogen response late, epithelial-mesenchymal transition, and UV response up (Table S1 ). Interestingly, genes defining late response to estrogen, epithelial-mesenchymal transition (such as in fibrosis and metastasis), and genes upregulated in response to ultraviolet (UV) radiation have not been fully elucidated in DLBCL. However, evidence suggests these genes have essential roles in oncogenesis. These findings provide evidence that can drive future research with therapeutic implications.

Our GO, KEGG, and GSEA analyses showed that the DEGs were enriched in some immune-related biological functions. Immune cell infiltration into tumors plays an essential role in tumorigenesis and metastasis. So, we applied the CIBERSORT algorithm to the GSE12453 dataset to predict immune cells infiltrating the TME. Among the immune subsets analyzed, activated memory CD4 + T cells, CD8 + T cells, and M0, M1, and M2 macrophages were the most represented cell fractions within the DLBCL microenvironment (Figs. 3A, 3B). The correlations among the TIICs ranged from high to negligible (Fig. S3 ). Regulatory T cells (Tregs) showed a moderate negative correlation with activated memory CD4 + T cells. However, M0 macrophages had a high positive correlation with activated memory CD4 + T cells and M1 macrophages. The varied infiltrating immune cell types could be reflective of the complexity and the unusual behavior of DLBCL. Uncommitted macrophages (M0) can polarize into the M1 (considered tumoricidal) and M2 (pro-tumorigenic) to show paradox effects on tumor prognosis (Dancsok et al., 2020) . Memory B cells and activated dendritic cells were the most represented fractions in the non-tumor controls (Fig. 3A) . The findings suggest that TIICs may be closely associated with clinical outcomes. Future studies, including their correlation to DLBCL disease stages, will be meaningful, particularly for immunotherapy.

We constructed the PPI network of all DEGs using the STRING database's multiple proteins function to determine genes likely to perform biological functions together. The highest confidence of 0.9 was set with unconnected nodes taken out. As shown in Fig. 4A , it yielded 609 nodes and 8,583 edges. These genes were highly inter-connected than expected (PPI enrichment p-value < 1.0e−16). We observed six important clusters with a k-score > 10 when we analyzed the tab-separated values (tsv) file with Cytoscape's MCODE. The largest cluster (#1) had the highest score of 33.17 (Fig. 4B ); it mainly comprised Ribosome genes (FDR = 3.49e−83) in KEGG analysis. Cluster 2 ( Fig. 4C ) was enriched in genes associated with oxidative phosphorylation (FDR, 7.23e−56) and Parkinson's disease (FDR, 2.62e−55). Cluster three ( Fig. 4D ) genes were mainly involved in chemokine signaling (FDR, 1.06e−22). We identified 109 highly connected DEGs (Excel S1) from these top three clusters. These DEGs could play essential roles in DLBCL, so they were selected for further hub gene screening. In this study, the down-regulated DEGs were not part of the constructed PPI, so we determined their relevance in DLBCL. We ranked the top 60 DEGs (30 up-and 30 down-regulated) by log 2 FC and analyzed them in the STRING database (Fig. S4A ). The only down-regulated DEG in the network built was identified upregulated when verified in the GEPIA2 database. To further investigate the down-regulated DEGs' functional relatedness, a PPI was constructed for all the down-regulated DEGs (Fig. S4B) . We found that the down-regulated genes were enriched in B cell activation for GO-BP, shown in (Fig. S4C) . Finally, we used the degree method of the CytoHubba application to predict the top 250 important genes (Fig. 4E ). Genes with a high degree of centrality are vital since they have many direct interacting gene partners. If confirmed, these critical findings could improve the general understanding and the potential causes of variation in the clinical prognosis of DLBCL. Weighted gene co-expression network (WGCNA) analysis

To identify co-expression modules that could share similar biological functions or regulatory mechanisms with clinical relevance to DLBCL, we applied the WGCNA package (Langfelder & Horvath, 2008; Langfelder & Horvath, 2012) in R (Team, 2019) . The GSE12453 dataset we processed was used. We carried out quality control procedures, including inspecting good genes and sample hierarchical clustering to detect potential outliers, but no obvious outliers were found (Fig. 5A) . The 35 samples yielded two main clusters. We applied the WGCNA on the top 25% of the 21,654 expressed genes ranked by the largest variance. To satisfy a scale-free network topology, we choose the soft-threshold power β of eight with R2 = 0.86 (Figs. 5B, 5C ). Hierarchical clustering and the dynamic tree-cutting yielded 18 modules of co-expressed genes (Fig. 5D ). Finally, we visualized the top 1,000 significantly expressed genes with a heatmap (Fig. 5E) ; they represent interesting genes for further analysis.

To investigate the molecular mechanisms of the traits, we correlated each Module Eigengenes (ME) to disease status (DLBCL and non-tumor controls). The results are shown in Fig. 6 . The ME turquoise and green (Figs. 6A, 6B) containing 292 and 72 genes, respectively, strongly correlated with DLBCL. ME dark magenta with five genes had the strongest negative correlation. The cut-off was set at gene significance (GS) value >0.8, and absolute Module Membership (MM) value >0.7. Besides, the GS versus MM plots for these three modules were highly correlated (Fig. 6C) , reflecting their high association with DLBCL. We selected these three clinically significant modules with the 369 high connectivity genes (gene list shown in Excel S1) for further analysis. The highly connected genes are often the most important (central) elements of the respective modules and tend to play key roles in the biological processes. The ME genes are listed in Excel S1. Altogether, these co-expressed genes might provide new clues to understand the biology of DLBCL in the future.

The 369 high connectivity genes from the three relevant modules were filtered in the STRING database followed by the Cytoscape; the network yielded a PPI with 195 nodes and 1,579 edges. The PPI and gene list are detailed in Fig. S5 and Excel S1. These 195 genes were considered functionally important. As presented in (Fig. 7) , functional annotation revealed that these genes were involved in viral transcription and viral gene expression in the BP category. In KEGG analysis, the genes were primarily enriched in ribosome, coronavirus disease-COVID-19, and oxidative phosphorylation. The identified pathways were roughly consistent with that of the DEGs. These processes and signaling pathways are usually disrupted in cancer and could provide an insight into the pathogenesis of DLBCL.

Eventually, we identified 46 important differentially co-expressed genes by the Venn diagram software, as shown in (Fig. 8A) . These 46 genes were common between the DEGs and WGCNA hub module genes and were regarded as hub genes. We re-analyzed the 46 genes with the STRING and Cytoscape databases, and the PPI is shown in (Fig. 8B) . Their GO and KEGG enrichments in the R software (Table 1) were similar to the other analyses. The KEGG common genes in the ribosome, COVID-19, and oxidative phosphorylation pathways are shown in Table 2 . The above pathway genes play essential roles in metabolic reprogramming and tumor-promoting inflammation of cancer and warrant further studies. Validation of expressions and prognostic analysis of core hub genes

We applied GEPIA2 to validate the reliability and authenticity of the 46 hub genes in the cancer genome atlas (TCGA) dataset. We identified 44 prognostic genes with higher expression (consistent with that in the GSE12453 dataset) in DLBCL tissues than the non-tumor control tissues (p < 0.01) ( Fig. 9 ) (15 genes shown) and (Excel S1). Kaplan-Meier survival analysis on the GSE31312 showed 15 of these genes (p < 0.05) correlated with patient outcomes (Fig. 10 & Table S2 ). Except for RPL11, the patients with high expressions had significantly shorter 5-year OS and PFS, suggesting these genes are potential oncogenes and have a role in DLBCL development and/or progression. The 15 genes (Fig. 11A) were considered as the core hub genes. Moreover, ROC curve analysis for their diagnostic potentials obtained AUCs ranging from 0.992 to 1.00, indicating optimal performance to accurately differentiate DLBCL from non-tumor control cases (Fig. S6) . Also, immunohistochemistry data from the human protein atlas (HPA) database demonstrated the protein expressions of some of the genes in some lymph node samples with cytoplasmic/membranous localization (Fig. S7 , four genes shown); data were retrieved from https://www.proteinatlas. The genes included RPS21, MRPS28, RPL31, and RPL30. As expected, they would be involved in metabolic pathways such as glycolysis and processes including signal transduction and cell division. The core hub genes' functional annotation was mainly associated with Ribosome and Coronavirus disease-COVID-19 (Figs. 11B, 11C; Table 3 ). To assess the tumorigenic potentials of the COVID-19 genes regarding immune cells infiltrating the TME, the ssGSEA analysis was applied (GSE31312). As shown in Fig. S8 , seven out of the nine COVID-19 pathway genes negatively correlated with mast cells, five with immature dendritic cell (iDC), and three genes negatively correlated with plasmacytoid DC. RPL30, RPL31, RPS25, and FAU positively correlated with tumor-infiltrating lymphocytes (TIL) and macrophages. RPL30, RPL31 correlated with Tregs. These infiltrating immune cells may be involved in regulating tumor proliferation, dormancy, and drug resistance. Finally, we determined whether the core genes were upregulated in other tumors. The GEPIA2 database revealed that all the 15 core genes were upregulated in thymoma (THYM), and 11 genes were upregulated in testicular germ cell tumors (TGCT). Notably, RPL30 and FAU genes were consistently upregulated in all six different cancer types identified (Table S3 ). In the Oncomine database, some of the core genes were upregulated in various lymphoma datasets and other cancers, including Sarcoma (Fig. S9) . The results suggest that the upregulation of these 15 hub genes may not be limited to DLBCL.

Diffuse large B-cell lymphoma (DLBCL) remains a significant clinical challenge; over 30% of patients are not cured (Pasqualucci & Dalla-Favera, 2018; Yi et al., 2020) . So far, no functional assays capable of screening exit, so effective management is required once diagnosed. Hence, identifying unique gene signatures and regulatory pathways related to its pathogenesis and prognosis is meaningful. Here, we examined the gene expression profile of GSE12453 to find dysregulated common core hub genes and pathways to help further understand DLBCL pathogenesis and provide potential biomarkers. Integrated bioinformatics analysis, gene expression levels, and survival analysis identified 15 differentially co-expressed core hub genes linked to DLBCL pathogenesis. The genes included RPS24, RPS21, RPL31, RPL30, RPS17, MRPS28, FAU, RPS25, RPL22L1, NDUFA6, CXCL9, CCL4, MRPL33, HEBP1, and RPL11. Their primary KEGG enrichment was ribosome and coronavirus disease-COVID-19, which was in line with the other analyses. The construction of ROC curves yielded very high AUC values suggesting the genes could accurately distinguish between DLBCL and non-tumor control cases and might be potential biomarkers. In addition, experimentally derived data from the HPA by IHC indicated the protein expression of some of the genes in some lymph node samples. RPS21, MRPS28, RPL31, and RPL30 showed relatively higher protein expressions in some DLBCL and other malignant lymphoma tissues than the averaged expressions in normal tissues, though not significant. The HPA database sample size was limited; however, the HPA experimental findings can be extended to DLBCL and other lymphomas, thus providing a valuable basis for medical and biological research. Lastly, most of the core genes were upregulated in different cancer types. Cancer is a complex disease, so the genes might have similar or different prognostic roles in these tumors. The overall survival data from GEPIA2 demonstrated that low levels of FAU, RPS17, and RPS 24 were significantly associated with shorter survival, while high CCL4 was significantly associated with shorter survival in thymoma patients. Nonetheless, the genes' potential biological and clinical relevance is not restricted to only DLBCL. These genes could be prognostic markers and therapeutic targets across different tumor types, particularly for patients with multiple coexisting tumors.

Little is known experimentally about the roles of most of the core genes proteins in DLBCL. However, dysregulated ribosomal proteins have been reported to play various critical roles in other tumors (Wang et al., 2015) . Among our ribosome genes, over-expressed RPS21 promoted prostate cancer (PCa) cell proliferation, migration, and invasion, inhibited PCa cell apoptosis, and was suggested as a promising biomarker, with a potential application in diagnosis or treatment (Liang et al., 2019) . The 8q-mapped RPL30 gene was associated with adverse outcomes in Medulloblastoma patients (De Bortoli et al., 2006) . RPS24 significantly promoted colorectal cancer (CRC) cells' proliferation rate and increased CRC risk in patients (Zou et al., 2020) . The knockdown of RPS24 inhibited cell proliferation and cell migration in human CRC cell lines and was recommended as a biomarker (Wang et al., 2015) . A study also implicated MRPS28 in the molecular pathogenesis of bladder cancer . The coronavirus disease-COVID-19 and viral transcription enrichments agree with recent studies implicating various viruses (Fedoriw et al., 2020) in the development and progression of DLBCL subtypes. Most DLBCL patients have an underlying immune dysfunction and can easily get viral infections. Viruses such as COVID 19 could manipulate the function of the COVID 19 related genes in the TME. Besides, the Gene Cards database (https://www.genecards.org/) demonstrated all the covid 19 pathway genes (RPS24, RPS21, RPL31, RPL30, RPS17, FAU, RPS25, RPL22L1, RPL11) are related to viral mRNA translation (Stelzer et al., 2016) . Additionally, the DAVID database (Protein interactions) associated five COVID 19 genes (RPL30, RPS17, RPS24, RPS25, and FAU) with HIV interactions (Huang, Sherman & Lempicki, 2009) .

Recently, hematological malignancies (HM) patients were reported to have a more severe COVID-19 trajectory than patients with solid organ tumors (Lee et al., 2020) . A significant number of the COVID 19 related genes were upregulated in various lymphomas and some multiple myeloma datasets (Fig. S9) . Most of our COVID-19 pathway genes showed some correlations with immune infiltrates such as TIL and macrophages. An anti-viral immune response can have protective effects with improved survival in coronavirus infection, but excessive inflammation can be harmful ("cytokine storm"). High pro-inflammatory macrophage (M1) and low CD8 + T cells were observed in the microenvironment of severe/critical COVID-19 patients (Liao et al., 2020) . Higher expression of CXCL9 in COVID-19 patients than healthy controls and higher levels of CCL4 in severe COVID-19 patients were also found (Liao et al., 2020) . These are partly consistent with our data and previous knowledge on various cancers (Brune et al., 2008; Chang et al., 2013; De la Fuente López et al., 2018) . Not much is known about COVID-19 and most cancers, including DLBCL pathogenesis. However, it is tempting to speculate that COVID-19 infection, together with the COVID-19 related genes, could increase macrophage polarization to M1 (hyper-inflammatory response) to worsen prognosis (He et al., 2020; Passamonti et al., 2020; Shah et al., 2020) . But, the mechanism is unclear, and limited data on the topic did not permit detailed discussion. However, extensive genome-related studies are required to verify this association between COVID 19 and DLBCL; these genes could provide a basis to identify effective preventive and therapeutic strategies.

Clinical implication analysis in the GEPIA2 database showed that the core hub genes were significantly overexpressed in DLBCL. The high expressions of 14 (93%) were negatively associated with prognostic outcomes (worse OS and PFS times). These emphasize their potential role as oncogenes and could be utilized as prognostic indicators for DLBCL. The high expression of RPL11 might be associated with a favorable clinical outcome (Kawahata et al., 2020; Kayama et al., 2017) . They offer unique opportunities for further investigation.

In addition to the ribosome (translation), the 46 hub genes were significantly represented in oxidative phosphorylation (OxPhos) and mitochondria inner membrane. Growing evidence suggests cancer is primarily a mitochondrial metabolic disease that exhibits altered energy production and dysregulated metabolic crosstalk (Yin et al., 2019; Norberg et al., 2017) . Their inhibition has demonstrated anti-cancer efficacy (Martínez-Reyes et al., 2020; Norberg et al., 2017) . Thus, with further studies, these metabolic genes could be rational targets, especially for the metabolically coupled and OxPhos-DLBCL subsets, and help understand the metabolic differences in DLBCL.

The few bioinformatics analyses on DLBCL focused on the subtypes (Huang, Liu & Shen, 2019; Zhou et al., 2020) or clinical features (Xiao, Wang & Bai, 2020) . However, some dysregulated genes specific to DLBCL versus non-tumor controls cannot distinguish the subtypes (Huang, Liu & Shen, 2019) . Moreover, most related studies that focused on DLBCL and non-cancer controls were based on DEGs (Huang, Liu & Shen, 2019; Luo et al., 2018) and discovered entirely different core hub genes. However, the complexity of DLBCL and the emergence of novel targeted therapies warrants more predictive personalized biomarkers for precision medicine. To our knowledge, no integrated bioinformatics analysis on DLBCL and non-tumor controls has so far been reported on the common core hub genes found and immune cells associations. Thus, our finding is novel.

One potential limitation of this study is the lack of experimental validation. However, this analysis provides a theoretical basis for our future work, which will focus on experimental verification. Second, an individual study with limited DLBCL cases was used, but the hub genes, pathways, and immune cells infiltrate identified are relevant to the pathogenesis of DLBCL and cannot be ignored. However, our results should be interpreted with caution.

We used the integrated bioinformatics method to highlight the critical roles of differentially co-expressed core hub genes and relevant pathways in DLBCL. We identified some immune-related core hub genes linked to DLBCL pathogenesis. The core genes' main KEGG pathway enrichments were Ribosome and Coronavirus disease-COVID-19. Their verification in GEPIA2 showed they were reliable. Nevertheless, most of the core genes were upregulated in different cancer types and hold potential biological and clinical relevance in cancers. Thus, the identified genes could be potential targets for prognosis and therapeutic intervention in DLBCL and may provide insight into the pathogenetic mechanisms in DLBCL.

Mengling Xu analyzed the data, authored or reviewed drafts of the paper, and approved the final draft. Zhimin Zhai conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft. Shudao Xiong conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

The following information was supplied regarding data availability:

Previously reported expression datasets were used in this study and are available at NCBI-GEO:

Dataset for differentially co-expressed genes identification

Dataset for survival and prognostic verification: GSE31312. The other databases used

Verification of hub gene expression levels and core hub gene expression levels in other tumors

Gene (names of the various hub genes)

Datasets Selection (Cancer name

A full list of the hub genes and cancer names is available in the Supplemental File

(Filters used: Differential Analysis and Gene Summary

Protein expression levels by immunohistochemistry (IHC): The human protein atlas database

Search terms for normal tissues: Tissue atlas

An automated method for finding molecular complexes in large protein interaction networks

Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis

Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and

Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi

EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

affy-analysis of Affymetrix GeneChip data at the probe level

COVID-19 in persons with haematological cancers

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

Involvement of ribosomal protein L11 expression in sensitivity of gastric cancer against 5-FU

GRWD1 negatively regulates p53 via the RPL11-MDM2 pathway and promotes tumorigenesis

WGCNA: an R package for weighted correlation network analysis

Fast R functions for robust correlations and hierarchical clustering

Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Centromere protein U enhances the progression of bladder cancer by promoting mitochondrial ribosomal protein s28 expression

Eleven genes associated with progression and prognosis of endometrial cancer (EC) identified by comprehensive bioinformatics analysis

Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study

DECODE: an integrated differential co-expression and differential expression analysis of gene expression data

Identification of potential drugs for diffuse large B-cell lymphoma based on bioinformatics and connectivity map database

Mitochondrial ubiquinol oxidation is necessary for tumour growth

Lymphomas in sub-Saharan Africa-what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?

Determining cell type abundance and expression from bulk tissues with digital cytometry

Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets

Genetics of diffuse large B-cell lymphoma

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

ONCOMINE: a cancer microarray database and integrated data-mining platform

Limma powers differential expression analyses for RNA-sequencing and microarray studies

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; king's college hospital experience

Cytoscape: a software environment for integrated models of biomolecular interaction networks

The GeneCards Suite: from gene data mining to disease genome sequence analyses

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

R: a language and environment for statistical computing. R foundation for statistical computing

A pathology atlas of the human cancer transcriptome

Gene co-expression analysis for functional classification and gene-disease predictions

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program study

RPS24 knockdown inhibits colorectal cancer cell migration and proliferation in vitro

Ggplot2: elegant graphics for data analysis

Clinical features and prognostic impact of coexpression modules constructed by WGCNA for diffuse large B-cell lymphoma

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy

clusterProfiler: an R package for comparing biological themes among gene clusters

Identification of hub genes associated with the pathogenesis of diffuse large B-cell lymphoma subtype one characterized by host response via integrated bioinformatic analyses

Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer

Three functional variants were identified to affect RPS24 expression and significantly associated with risk of colorectal cancer

 GSM312870  GSM312872  GSM312874  GSM312875  GSM312876  GSM312877  GSM312879  GSM312882  GSM312883  GSM312886  GSM312890  GSM312893  GSM312894  GSM312895  GSM312937  GSM312938  GSM312939  GSM312940  GSM312941  GSM312942  GSM312943  GSM312944  GSM312945  GSM312946  GSM312858  GSM312859  GSM312860  GSM312861  GSM312862  GSM312863  GSM312864  GSM312865  GSM312867  GSM312868  GSM312869 

The authors declare that they have no competing interests.

Alice Charwudzi conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft. Ye Meng conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft. Linhui Hu performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft. Chen Ding performed the experiments, authored or reviewed drafts of the paper, and approved the final draft. Lianfang Pu analyzed the data, authored or reviewed drafts of the paper, and approved the final draft. Qian Li analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.12394#supplemental-information.